Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290

Completed

Conditions studied: Recurrent Endometrial Carcinoma

In brief

This trial assesses blood and tumor samples for the effect of trametinib with or without uprosertib on biomarkers in patients enrolled on trial GOG02290 with endometrial cancer that is persistent or has come back. Biomarkers found in the blood and tissue may be related to the reaction or response to the study drugs.

Key facts

Study ID

NCT02093546

Run by

M.D. Anderson Cancer Center

People needed

40

Starts

2004-08-13

Expected to finish

2020-01-15

Last updated by the study team

2020-01-28

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be enrolled on GOG0229O
• Patients must have tissue available for molecular analysis. This can be tissue obtained at time of current recurrence or archival tissue from primary diagnosis or recurrence
• Patients must have disease lesions that are amenable to pre- and post- treatment biopsy
• Patients must have signed an approved informed consent and authorization permitting release of personal health information

You may not qualify if…

• Patients unwilling to undergo a biopsy

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.